Trending Stock News

Calamos Wealth Management Has Lowered Its Stake in Newell Brands (NWL) by $486,275 as Stock Value Rose; Valeant Pharmaceuticals Intl (VRX) Market Value Declined While Stanley Capital Management Upped Holding

Calamos Wealth Management Llc decreased its stake in Newell Brands Inc (NWL) by 39.62% based on its latest 2017Q2 regulatory filing with the SEC. Calamos Wealth Management Llc sold 9,175 shares as the company’s stock rose 13.21% with the market. The institutional investor held 13,982 shares of the plastic products company at the end of 2017Q2, valued at $750,000, down from 23,157 at the end of the previous reported quarter. Calamos Wealth Management Llc who had been investing in Newell Brands Inc for a number of months, seems to be less bullish one the $14.86 billion market cap company. The stock decreased 0.52% or $0.16 during the last trading session, reaching $30.32. About 3.70M shares traded. Newell Brands Inc. (NYSE:NWL) has risen 11.94% since December 15, 2016 and is uptrending. It has underperformed by 4.76% the S&P500.

Stanley Capital Management Llc increased its stake in Valeant Pharmaceuticals Intl (VRX) by 21.38% based on its latest 2017Q2 regulatory filing with the SEC. Stanley Capital Management Llc bought 33,200 shares as the company’s stock declined 15.71% while stock markets rallied. The institutional investor held 188,500 shares of the health care company at the end of 2017Q2, valued at $3.26 million, up from 155,300 at the end of the previous reported quarter. Stanley Capital Management Llc who had been investing in Valeant Pharmaceuticals Intl for a number of months, seems to be bullish on the $6.95 billion market cap company. The stock increased 1.35% or $0.265 during the last trading session, reaching $19.945. About 16.94 million shares traded or 5.63% up from the average. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has declined 48.51% since December 15, 2016 and is downtrending. It has underperformed by 65.21% the S&P500.

Analysts await Newell Brands Inc. (NYSE:NWL) to report earnings on February, 5. They expect $0.75 EPS, down 6.25% or $0.05 from last year’s $0.8 per share. NWL’s profit will be $367.58M for 10.11 P/E if the $0.75 EPS becomes a reality. After $0.86 actual EPS reported by Newell Brands Inc. for the previous quarter, Wall Street now forecasts -12.79% negative EPS growth.

Among 19 analysts covering Newell Rubbermaid Inc. (NYSE:NWL), 11 have Buy rating, 0 Sell and 8 Hold. Therefore 58% are positive. Newell Rubbermaid Inc. had 53 analyst reports since August 4, 2015 according to SRatingsIntel. The firm earned “Strong Buy” rating on Tuesday, November 8 by Raymond James. The rating was downgraded by JP Morgan on Thursday, November 2 to “Neutral”. RBC Capital Markets downgraded the shares of NWL in report on Friday, November 3 to “Outperform” rating. The firm has “Outperform” rating given on Tuesday, November 15 by Wells Fargo. The rating was maintained by SunTrust with “Buy” on Wednesday, October 18. The rating was upgraded by RBC Capital Markets to “Top Pick” on Wednesday, December 16. The rating was maintained by RBC Capital Markets on Thursday, June 8 with “Buy”. UBS maintained the stock with “Buy” rating in Monday, May 2 report. Forward View Consulting maintained the shares of NWL in report on Friday, September 8 with “Buy” rating. Piper Jaffray upgraded the shares of NWL in report on Tuesday, December 15 to “Overweight” rating.

Calamos Wealth Management Llc, which manages about $927.87 million and $706.73M US Long portfolio, upped its stake in Cisco Systems Inc (NASDAQ:CSCO) by 50,013 shares to 201,533 shares, valued at $6.31M in 2017Q2, according to the filing. It also increased its holding in Ishares Core Msci Emerging (IEMG) by 10,150 shares in the quarter, for a total of 99,758 shares, and has risen its stake in Goldman Sachs (NYSE:GS).

Investors sentiment decreased to 0.94 in 2017 Q2. Its down 0.17, from 1.11 in 2017Q1. It turned negative, as 57 investors sold NWL shares while 227 reduced holdings. 72 funds opened positions while 196 raised stakes. 441.31 million shares or 0.62% less from 444.05 million shares in 2017Q1 were reported. Waddell And Reed Fincl Inc holds 3.90M shares. The Alabama-based Warren Averett Asset Mgmt Lc has invested 0.08% in Newell Brands Inc. (NYSE:NWL). Capstone Asset stated it has 0.04% in Newell Brands Inc. (NYSE:NWL). The Illinois-based Nuveen Asset Mgmt Limited Liability Company has invested 0.11% in Newell Brands Inc. (NYSE:NWL). Huntington National Bank & Trust has 196,508 shares for 0.18% of their portfolio. Bowen Hanes & Co has 541,005 shares for 1.42% of their portfolio. Toronto Dominion Commercial Bank owns 0.03% invested in Newell Brands Inc. (NYSE:NWL) for 168,861 shares. Nippon Life Communications stated it has 22,271 shares. L And S has invested 1.34% in Newell Brands Inc. (NYSE:NWL). Fiduciary Tru invested in 5,805 shares. Putnam Invests Limited Liability Company holds 0% of its portfolio in Newell Brands Inc. (NYSE:NWL) for 9,464 shares. Clearbridge Investments Limited Company has invested 0% in Newell Brands Inc. (NYSE:NWL). Cap Mgmt Assoc Ny has 28,189 shares for 2.28% of their portfolio. Kingdon Cap Mgmt has 2.86% invested in Newell Brands Inc. (NYSE:NWL). Utd Ser Automobile Association holds 339,858 shares or 0.06% of its portfolio.

Among 27 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 6 have Buy rating, 5 Sell and 16 Hold. Therefore 22% are positive. Valeant Pharmaceuticals Intl had 147 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Hold” rating by BTIG Research on Thursday, November 9. Morgan Stanley downgraded the shares of VRX in report on Thursday, December 15 to “Equal-Weight” rating. The company was maintained on Tuesday, February 14 by RBC Capital Markets. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Equal-Weight” rating given on Wednesday, March 16 by Morgan Stanley. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Sector Perform” rating by RBC Capital Markets on Wednesday, November 9. The firm has “Hold” rating given on Wednesday, March 16 by Canaccord Genuity. On Friday, November 3 the stock rating was maintained by TD Securities with “Hold”. As per Monday, August 21, the company rating was maintained by H.C. Wainwright. On Wednesday, March 2 the stock rating was downgraded by Canaccord Genuity to “Hold”. On Wednesday, June 8 the stock rating was maintained by Stifel Nicolaus with “Buy”.

Investors sentiment decreased to 1.08 in 2017 Q2. Its down 0.16, from 1.24 in 2017Q1. It dropped, as 53 investors sold VRX shares while 76 reduced holdings. 49 funds opened positions while 90 raised stakes. 171.89 million shares or 1.47% more from 169.41 million shares in 2017Q1 were reported. Aperio Gp Limited Liability Corporation reported 0.01% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Scotia Cap has 0.01% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Benjamin F Edwards And Company has invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Iron Finance Ltd Llc reported 0.18% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Private Advisor Group Incorporated Limited Liability Co holds 0.01% or 25,633 shares in its portfolio. Pentwater Cap Mgmt Limited Partnership reported 0.12% stake. Massachusetts Financial Ma owns 186,346 shares or 0% of their US portfolio. 599 are owned by Valley National Advisers. 76,792 were accumulated by Raymond James Financial Serv Advsr. 690 were reported by Kemnay Advisory. Tb Alternative Assets Ltd stated it has 1.98% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Airain Limited has 0.03% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 38,566 shares. Rbf Capital Limited Liability Corporation stated it has 131,100 shares or 0.3% of all its holdings. Services Corp has 0% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Swiss Savings Bank reported 1.25 million shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *